Why the study?
Do different beta-blockers (atenolol, carvedilol, bisoprolol, nebivolol) have differing effects on insulin resistance and lipid metabolism in patients with hypertension and metabolic syndrome?
Do different beta-blockers (atenolol, carvedilol, bisoprolol, nebivolol) have differing effects on insulin resistance and lipid metabolism in patients with hypertension and metabolic syndrome?
In patients with hypertension and metabolic syndrome, newer beta-blockers like nebivolol, carvedilol, and bisoprolol improve or maintain insulin sensitivity and lipid profiles, whereas atenolol worsens them.
For years the use of beta-blockers in patients with metabolic syndrome has been limited due to the negative impact of non-selective beta -blockers on carbohydrate and lipid metabolism.
No takes yet. Share an insight, caveat, or question.
Yu.M. Sіrenko (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: